Sign in
Taking people in United StatesNo phase

Lifeline stent for babies born with congenital heart disease

Tests the Lifeline stent in babies with congenital heart disease.

Key facts

Who runs it
Starlight Cardiovascular Inc
Where
Aurora, Baltimore, Boston, Cincinnati, Columbus, Houston, Los Angeles, Philadelphia, San Diego, Seattle, and Stanford, United StatesSee the 11 sites
Trial code
Registry title
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Status
Recruiting
People taking part
45 people, planned
Started
16 Jan 2026
Expected to end
Apr 2028
Type of study
Interventional
Treatments tested
  • Ductus Arteriosus Stent
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for babies under 6 months old with a heart defect present from birth. Their lung blood flow depends on an open ductus arteriosus (a blood vessel near the heart). The trial tests a stent that keeps this vessel open.

Age
From 1 minute to 6 months old (under 6 months).
Sex
All sexes.
Disease stage
Heart defect from birth where blood flow to the lungs depends on the ductus arteriosus and needs prostaglandin infusion. The baby needs a stent 3.5mm or 4mm wide and 16mm to 28mm long.
Earlier treatment
Must be getting a prostaglandin infusion. Cannot join if on ECMO, a ventricular assist device or dialysis before the stent procedure. Cannot join if another catheter procedure is done during or within 24 hours before stenting.

Main reasons for not taking part

  • Active blood infection, or current or past endocarditis (heart lining infection).
  • Body weight under 2.5kg (6 lb (3 kg)), or born before 32 weeks of pregnancy.
  • Complete heart block, total anomalous pulmonary venous return, or certain other heart anatomy problems.
  • Allergy to nickel, or contrast dye allergy that cannot be handled with medicine beforehand.
  • Cannot take blood thinners around the procedure, or known not to respond to aspirin or other antiplatelet drugs.

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Parental or legal authorized representative provide consent for study enrollment
  • Infants < 6 months of age
  • Diagnosis of congenital heart defect with ductal-dependent pulmonary circulation requiring infusion of prostaglandins
  • Requires ductus arteriosus stent diameters of 3.5mm or 4mm and stent lengths between 16mm and 28mm

Who cannot take part

  • Currently participating in an investigational drug study or another device study that would confound the study results
  • Patient who is on extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), or dialysis prior to ductal stenting procedure
  • Patient who is undergoing another transcatheter procedure (e.g., atrial septostomy, aortic arch intervention, or right ventricular outflow tract intervention) during or within 24 hours prior to the ductus arteriosus stenting procedure
  • Patient who, at the time of enrollment, is deemed not to be a candidate for eventual stage II palliation of single ventricle heart disease, complete surgical repair, nor transcatheter treatment with resultant biventricular circulation
  • Patient who does not plan to return to the enrolling center or another participating center for stage II palliation, complete surgical repair, or definitive catheterization procedure
  • Known to be non-responsive to aspirin or other antiplatelet therapies
  • Active blood stream infection
  • Active or history of endocarditis
  • Complete heart block
  • Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.)
  • Known hypersensitivity or allergy to Nickel
  • Known hypersensitivity to contrast media that cannot be adequately pre-medicated
  • Gestational age <32 weeks at birth
  • Body weight <2.5kg
  • Total Anomalous Pulmonary Venous Return
  • Anatomic variation judged to be inappropriate for ductal stenting per the treating interventionalist
  • Presence of an aortopulmonary collateral that is expected to require unifocalization
  • Non-confluent pulmonary arteries (i.e. isolated pulmonary artery of ductal origin) or bilateral patent ductus arteriosus (PDA)
  • Pulmonary atresia with intact ventricular septum with RV-dependent coronary circulation
  • Contraindications to peri-procedural anticoagulation

Where in United States

  • Children's Hospital ColoradoAurora, United StatesContact: Maria DornonTaking people
  • Johns Hopkins Children's CenterBaltimore, United StatesContact: Kate KalligyNot yet recruiting
  • Boston Children's HospitalBoston, United StatesContact: Lizzy CooneyTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Amy PajkTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Victoria ShayTaking people
  • Texas Children's Hospital/ Baylor College of MedicineHouston, United StatesContact: Lesley CruzTaking people
  • UCLA Mattel Children'sLos Angeles, United StatesContact: Nicholas SharawayTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Olivia MartinoTaking people
  • Rady Children's Hospital - San DiegoSan Diego, United StatesContact: Yu XiaoyangTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Jeremy GillisTaking people
  • Leland Stanford Junior UniversityStanford, United StatesContact: Kifle YohannesTaking people

About the trial

What the trial wants to find out

Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System. The study device is a stent that is designed to maintain patency of the Ductus Arteriosus for children who need blood flow through that part of the heart.

The group in the trial

  • Single Arm - TreatmentOther group

    Treatment with the Lifeline Ductus Arteriosus Stent

    Treatment: Ductus Arteriosus Stent

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Plain-language title
Lifeline stent for babies born with congenital heart diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 October 2026